Published in J Histochem Cytochem on September 04, 2013
Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene (2002) 2.74
Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem (2000) 2.50
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem (2000) 2.47
Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem (2006) 2.07
Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem (1999) 1.93
Hair follicle predetermination. J Cell Sci (2001) 1.92
The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem (2003) 1.71
Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. Am J Hum Genet (2007) 1.56
Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci U S A (2007) 1.52
Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem (2001) 1.49
Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem (1997) 1.36
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer. Cancer Res (2010) 1.32
Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am J Pathol (2006) 1.32
Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J Biol Chem (2008) 1.31
Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem (2003) 1.29
Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition. Am J Physiol Cell Physiol (2009) 1.27
Ichthyosis, follicular atrophoderma, and hypotrichosis caused by mutations in ST14 is associated with impaired profilaggrin processing. J Invest Dermatol (2008) 1.26
Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling. FASEB J (2000) 1.26
Matriptase activation, an early cellular response to acidosis. J Biol Chem (2009) 1.24
Regulation of the matriptase-prostasin cell surface proteolytic cascade by hepatocyte growth factor activator inhibitor-1 during epidermal differentiation. J Biol Chem (2010) 1.19
Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1. Am J Physiol Cell Physiol (2008) 1.15
Collagens in the liver extracellular matrix bind hepatocyte growth factor. Gastroenterology (1998) 1.10
Electron microscopic study on cell differentiation in anagen hair follicles in mice. J Invest Dermatol (1988) 1.07
Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem (2000) 1.06
Autosomal recessive ichthyosis with hypotrichosis syndrome: further delineation of the phenotype. Clin Genet (2008) 1.03
TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells. Am J Pathol (2010) 0.97
Growth factors specifically alter hair follicle cell proliferation and collagenolytic activity alone or in combination. Differentiation (1990) 0.96
The optimal activity of a pseudozymogen form of recombinant matriptase under the mildly acidic pH and low ionic strength conditions. J Biochem (2009) 0.93
Mechanisms for the control of matriptase activity in the absence of sufficient HAI-1. Am J Physiol Cell Physiol (2011) 0.92
Antithrombin regulates matriptase activity involved in plasmin generation, syndecan shedding, and HGF activation in keratinocytes. PLoS One (2013) 0.92
Increased matriptase zymogen activation in inflammatory skin disorders. Am J Physiol Cell Physiol (2010) 0.89
Identification of clustered cells in human hair follicle responsible for MMP-9 gelatinolytic activity: consequences for the regulation of hair growth. Int J Dermatol (2001) 0.86
Hair cycle-dependent expression of hepatocyte growth factor (HGF) activator, other proteinases, and proteinase inhibitors correlates with the expression of HGF in rat hair follicles. J Investig Dermatol Symp Proc (1999) 0.86
Hepatocyte growth factor/scatter factor expressed in follicular papilla cells stimulates human hair growth in vitro. J Cell Physiol (1995) 0.86
Correlation of proteolytic activities of organ cultured intact mouse skin with defined hair cycle stages. J Dermatol Sci (1994) 0.85
The effect of hepatocyte growth factor/scatter factor on human hair follicle growth. J Dermatol Sci (1995) 0.85
Matriptase regulates proliferation and early, but not terminal, differentiation of human keratinocytes. J Invest Dermatol (2013) 0.84
Relationship between urokinase plasminogen activator receptor (uPAR) and the invasion of human prenatal hair follicle. Arch Dermatol Res (2009) 0.78
A novel in-situ-zymography technique localizes gelatinolytic activity in human skin to mast cells. Exp Dermatol (1998) 0.78
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat (2006) 4.04
Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med (2007) 3.36
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem (2007) 3.07
Liberal versus restricted fluid resuscitation strategies in trauma patients: a systematic review and meta-analysis of randomized controlled trials and observational studies*. Crit Care Med (2014) 2.39
GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat (2005) 2.30
4E-BP functions as a metabolic brake used under stress conditions but not during normal growth. Genes Dev (2005) 2.28
Local protease signaling contributes to neural tube closure in the mouse embryo. Dev Cell (2010) 2.19
Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem (2006) 2.07
Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia (2005) 2.04
The growth regulators warts/lats and melted interact in a bistable loop to specify opposite fates in Drosophila R8 photoreceptors. Cell (2005) 2.00
Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis - a systemic review and meta-analysis. PLoS One (2013) 1.94
Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol (2006) 1.88
Krüppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression. PLoS One (2012) 1.87
Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood (2014) 1.81
Characterization of matriptase expression in normal human tissues. J Histochem Cytochem (2003) 1.74
Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A (2007) 1.71
Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cell Dev Biol Anim (2004) 1.71
The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem (2003) 1.71
Drosophila Melted modulates FOXO and TOR activity. Dev Cell (2005) 1.59
Multiple hepatic peribiliary cysts with cirrhosis. J Gastroenterol (2004) 1.57
HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am J Physiol Cell Physiol (2005) 1.56
Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci U S A (2010) 1.52
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res (2002) 1.44
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. Onkologie (2010) 1.44
Personal characteristics, knowledge of the veterinary profession, and influences on career choice among students in the veterinary school applicant pool. J Am Vet Med Assoc (2003) 1.43
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev (2006) 1.41
Images in clinical medicine. Giant ovarian cyst. N Engl J Med (2008) 1.41
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics (2003) 1.39
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer. Cancer Res (2010) 1.32
Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J Biol Chem (2008) 1.31
Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching. J Biol Chem (2002) 1.30
Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells. Am J Physiol Cell Physiol (2004) 1.29
Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis (2004) 1.29
Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition. Am J Physiol Cell Physiol (2009) 1.27
Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain. Am J Physiol Cell Physiol (2007) 1.27
Recombinase-mediated cassette exchange provides a versatile platform for gene targeting: knockout of miR-31b. Genetics (2009) 1.26
Active properties of motoneurone dendrites: diffuse descending neuromodulation, focused local inhibition. J Physiol (2007) 1.26
Intrinsic electrical properties of spinal motoneurons vary with joint angle. Nat Neurosci (2007) 1.24
Matriptase activation, an early cellular response to acidosis. J Biol Chem (2009) 1.24
Zymogen activation, inhibition, and ectodomain shedding of matriptase. Front Biosci (2008) 1.24
Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene (2002) 1.22
Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. J Biol Chem (2002) 1.21
Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for branching morphogenesis in the chorioallantoic placenta. Mol Cell Biol (2005) 1.20
Regulation of the matriptase-prostasin cell surface proteolytic cascade by hepatocyte growth factor activator inhibitor-1 during epidermal differentiation. J Biol Chem (2010) 1.19
The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor. Cancer Res (2007) 1.19
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol (2012) 1.18
Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem (2007) 1.18
Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1. Am J Physiol Cell Physiol (2008) 1.15
In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate cancer models. Prostate (2006) 1.14
Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis (2002) 1.12
A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. Neoplasia (2008) 1.12
Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res (2009) 1.12
Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis. Appl Immunohistochem Mol Morphol (2009) 1.12
Malignant mesenchymal tumor with leiomyosarcoma, rhabdomyosarcoma, chondrosarcoma, and osteosarcoma differentiation: case report and literature review. Diagn Pathol (2011) 1.11
Missed brown tumors in a young adult with decreased bone density. South Med J (2010) 1.11
Defect of hepatocyte growth factor activator inhibitor type 1/serine protease inhibitor, Kunitz type 1 (Hai-1/Spint1) leads to ichthyosis-like condition and abnormal hair development in mice. Am J Pathol (2008) 1.11
Personality and citizenship behavior: the mediating role of job satisfaction. J Appl Psychol (2009) 1.11
Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem (2004) 1.10
Merkel cell carcinoma arising from the subcutaneous fat of the arm with intact skin. Dermatol Surg (2005) 1.10
Comparison of mouse mammary gland imaging techniques and applications: reflectance confocal microscopy, GFP imaging, and ultrasound. BMC Cancer (2008) 1.10
A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation. J Biol Chem (2013) 1.09
Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res (2009) 1.08
Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci (2004) 1.08
S1P/S1P1 signaling stimulates cell migration and invasion in Wilms tumor. Cancer Lett (2009) 1.08
Tophaceous gout of the knee: revisiting MRI patterns in 30 patients. J Clin Rheumatol (2010) 1.07
Of mice and Myc: c-Myc and mammary tumorigenesis. J Mammary Gland Biol Neoplasia (2004) 1.07
Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. Am J Physiol Cell Physiol (2006) 1.06
Active dendritic integration of inhibitory synaptic inputs in vivo. J Neurophysiol (2003) 1.06
The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat (2008) 1.06
Thermodynamics of aminoglycoside-rRNA recognition. Biopolymers (2003) 1.06
Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI. Cell Cycle (2006) 1.06
Calmodulin modulates Akt activity in human breast cancer cell lines. Breast Cancer Res Treat (2008) 1.06
Role of angiogenic and non-angiogenic mechanisms in oral squamous cell carcinoma: correlation with histologic differentiation and tumor progression. J Oral Pathol Med (2004) 1.06
The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells. Biochim Biophys Acta (2007) 1.05
Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2006) 1.05
CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells. Carcinogenesis (2009) 1.05
Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J Biol Chem (2009) 1.04
Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci (2006) 1.03
Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol (2003) 1.03
3-Phenyl substituted 6,7-dimethoxyisoquinoline derivatives as FtsZ-targeting antibacterial agents. Bioorg Med Chem (2012) 1.03
Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo. PLoS One (2009) 1.03
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci (2007) 1.02